$PUMA BIOTECHNOLOGY INC(PBYI)$ AF:" I've been skeptical about a Puma takeout mainly because 1) neratinib faces significant competition, particularly in its lead breast cancer indication; and 2) the drug causes a lot of diarrhea, which will make it unpopular with patients." 网页链接